Joan Crawford, DO
Cardiovascular Disease · Bloomington, INNPI 1124077953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,555 of the $76,957 with a category attached, or 78.7%. Lantheus Medical Imaging, Inc. accounts for 93.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $22,524 and has fallen 94.9% since, to $1,160 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $450.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$72K
- Abbott$973
- Boston Scientific$660
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$481
- Kestra Medical Technology Services, Inc.$377
- Actelion Pharmaceuticals US, Inc.$373
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,4003%
- Speaking & faculty fees$60,55579%
- Travel & lodging$6,8549%
- Food & beverage$7,1299%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 94 | $71,756 |
| Abbott | 7 | $973 |
| Boston Scientific | 8 | $660 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $481 |
| Kestra Medical Technology Services, Inc. | 3 | $377 |
| Actelion Pharmaceuticals US, Inc. | 4 | $373 |
| Shockwave Medical, Inc | 2 | $339 |
| Medtronic | 2 | $278 |
| Inari Medical, Inc. | 2 | $197 |
| Amgen | 4 | $180 |
| Boehringer Ingelheim | 2 | $138 |
| Merck | 2 | $136 |
| Atricure, Inc. | 1 | $134 |
| Abiomed | 1 | $132 |
| AstraZeneca | 1 | $125 |
| GE HealthCare | 1 | $120 |
| Cardiva Medical, Inc. | 2 | $118 |
| Ablative Solutions, Inc. | 1 | $110 |
| Preventice Services, LLC | 1 | $88 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Biosense Webster, Inc. | 2 | $61 |
| Heartflow, Inc. | 2 | $47 |
| Pfizer | 2 | $28 |
| Novartis | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$70,424
- PRESSUREWIRE$354
- OPSUMIT$352
- Assure WCD$342
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$339
- CardioMEMS HF System$283
- VERQUVO$238
- UPTRAVI$229
- FLOWTRIEVER CATHETER, S$175
- CT THROMBECTOMY SYSTEM KIT$175
- INTERSTIM$170
- HeartMate 3 Left Ventricular Dev$164
- CARDIOMEMS$147
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$134
- ATRICLIP LAA EXCLUSION SYSTEM$134
- Impella$132
- EMBLEM MRI S-ICD$127
- Repatha$126
- FARXIGA$125
- WATCHMAN Access System$122
How this compares
$76,957 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 280 | $361,789 |
| EntrestoSacubitril/Valsartan | 91 | $146,645 |
| XareltoRivaroxaban | 67 | $96,293 |
| MultaqDronedarone Hcl | 13 | $16,570 |
| BrilintaTicagrelor | 16 | $11,400 |
| Metoprolol Succinate | 416 | $8,780 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,569 |
| Atorvastatin Calcium | 341 | $5,290 |
| Ranolazine ErRanolazine | 38 | $4,391 |
| Carvedilol | 261 | $4,185 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 94 | $3,969 |
| Losartan Potassium | 259 | $3,304 |
| Rosuvastatin Calcium | 138 | $3,218 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 112 | $2,852 |
| ClopidogrelClopidogrel Bisulfate | 131 | $2,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $361,789280 claims |
| NovartisEntresto | $14 | $146,64591 claims |
| Johnson & JohnsonXarelto | $11 | $96,29367 claims |
| AstraZenecaBrilinta | $125 | $11,40016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Bloomington
- Lawrence RinkBloomington$280K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.